» Articles » PMID: 25689103

Autoantibodies to Multiple Epitopes on the Non-Collagenous-1 Domain of Type VII Collagen Induce Blisters

Abstract

Epidermolysis bullosa acquisita (EBA) is an autoimmune blistering disease of the skin and mucous membranes, characterized by autoantibodies against type VII collagen (COL7), a major component of anchoring fibrils. Different clinical EBA phenotypes are described, including mechanobullous and inflammatory variants. Most EBA patients' sera react with epitopes located within the non-collagenous 1 (NC1) domain of human COL7. However, it has remained unclear whether antibody binding to these different epitopes is pathogenically relevant. To address this issue, we generated recombinant proteins covering the entire NC1 domain. IgG reactivity with these proteins was analyzed in sera of 69 EBA patients. Most recognized clusters of epitopes throughout the NC1 domain. No correlation was detected between antibody specificity and clinical phenotype. To study the pathogenicity of antibodies specific to different NC1 subdomains, rabbit antibodies were generated. All these antibodies caused dermal-epidermal separation ex vivo. Antibodies against two of these subdomains were injected into mice carrying null mutations of mouse COL7 and the human COL7 transgene and induced subepidermal blisters. We here document that autoantibodies to COL7, independent of the targeted epitopes, induce blisters both ex vivo and in vivo. In addition, using COL7-humanized mice, we provide in vivo evidence of pathogenicity of autoantibodies binding to human COL7.

Citing Articles

Therapeutic base editing and prime editing of COL7A1 mutations in recessive dystrophic epidermolysis bullosa.

Hong S, Kim S, Lee A, Hwang G, Kim J, Iwata H Mol Ther. 2022; 30(8):2664-2679.

PMID: 35690907 PMC: 9372317. DOI: 10.1016/j.ymthe.2022.06.005.


Topical Application of the PI3Kβ-Selective Small Molecule Inhibitor TGX-221 Is an Effective Treatment Option for Experimental Epidermolysis Bullosa Acquisita.

Zillikens H, Kasprick A, Osterloh C, Gross N, Radziewitz M, Hass C Front Med (Lausanne). 2021; 8:713312.

PMID: 34557502 PMC: 8452940. DOI: 10.3389/fmed.2021.713312.


Epidermolysis Bullosa Acquisita: The 2019 Update.

Koga H, Prost-Squarcioni C, Iwata H, Jonkman M, Ludwig R, Bieber K Front Med (Lausanne). 2019; 5:362.

PMID: 30687710 PMC: 6335340. DOI: 10.3389/fmed.2018.00362.


Therapeutic Effect of a Novel Phosphatidylinositol-3-Kinase δ Inhibitor in Experimental Epidermolysis Bullosa Acquisita.

Koga H, Kasprick A, Lopez R, Auli M, Pont M, Godessart N Front Immunol. 2018; 9:1558.

PMID: 30050528 PMC: 6052048. DOI: 10.3389/fimmu.2018.01558.

References
1.
Schmidt E, Zillikens D . Pemphigoid diseases. Lancet. 2012; 381(9863):320-32. DOI: 10.1016/S0140-6736(12)61140-4. View

2.
Dahl M . Epidermolysis bullosa acquisita--a sign of cicatricial pemphigoid?. Br J Dermatol. 1979; 101(4):475-84. DOI: 10.1111/j.1365-2133.1979.tb00030.x. View

3.
Csorba K, Sesarman A, Oswald E, Feldrihan V, Fritsch A, Hashimoto T . Cross-reactivity of autoantibodies from patients with epidermolysis bullosa acquisita with murine collagen VII. Cell Mol Life Sci. 2010; 67(8):1343-51. PMC: 11115820. DOI: 10.1007/s00018-009-0256-3. View

4.
Lapiere J, Woodley D, Parente M, Iwasaki T, Wynn K, Christiano A . Epitope mapping of type VII collagen. Identification of discrete peptide sequences recognized by sera from patients with acquired epidermolysis bullosa. J Clin Invest. 1993; 92(4):1831-9. PMC: 288347. DOI: 10.1172/JCI116774. View

5.
Hirose M, Recke A, Beckmann T, Shimizu A, Ishiko A, Bieber K . Repetitive immunization breaks tolerance to type XVII collagen and leads to bullous pemphigoid in mice. J Immunol. 2011; 187(3):1176-83. DOI: 10.4049/jimmunol.1100596. View